Jagsonpal Pharmaceuticals has entered into a Business Transfer Agreement (BTA) with Group Pharmaceuticals (Seller) on 23 September 2026, for acquisition of the Wellness Portfolio of the Seller, on a going-concern basis by way of slump sale, subject to the terms and conditions contained in the BTA.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.